Continuous Glucose Monitoring (CGM) Market Trends

Continuous Glucose Monitoring (CGM) Market Overview

Global Continuous Glucose Monitoring (CGM) market size is anticipated to be worth USD 1529.4 million in 2025, projected to reach USD 2647.3 million by 2034 at a 6.29% CAGR.

The Continuous Glucose Monitoring (CGM) market is experiencing rapid adoption driven by the rising population living with diabetes, with more than 537 million global cases reported in 2021 and expected to exceed 643 million by 2030. The increasing acceptance of real-time CGM devices across over 55% of insulin-dependent patients in developed nations is shaping new demand patterns. Wearable CGM systems have gained traction, with over 46% of Type 1 diabetes patients in North America using CGM devices as part of their standard care. The rising preference for minimally invasive sensors and digital health integration is increasing demand for CGM systems in the hospital and homecare environment. With over 2.2 million new CGM users added globally in 2023, the market continues to grow in terms of technology adoption rather than revenue metrics. The shift toward smartphone-connected sensors, Bluetooth-enabled transmitters, and 14-day wear sensors is becoming standard, with over 70% of new CGM devices launched after 2022 offering wireless connectivity.

The increasing penetration of insulin pumps—used by over 4.5 million patients globally—strengthens CGM-pump integration demand. Rising awareness across the Asia-Pacific region, where diabetes prevalence reaches 11.9% in countries like China and 9.6% in India, is accelerating CGM market expansion. This Continuous Glucose Monitoring (CGM) Market Report provides in-depth Continuous Glucose Monitoring (CGM) Market Analysis, CGM Industry Analysis, CGM Market Trends, CGM Market Share insights, Continuous Glucose Monitoring (CGM) Market Forecast, and B2B-focused CGM Market Opportunities for manufacturers, distributors, health-tech providers, and investors.

The USA represents the world’s most advanced CGM market, with more than 37.3 million Americans diagnosed with diabetes, and over 1.6 million Type 1 patients particularly dependent on glucose monitoring solutions. As of 2024, nearly 65% of US Type 1 diabetes patients use CGM devices, supported by strong insurance coverage from over 90% of major health plans. The presence of leading manufacturers such as Dexcom and Abbott accelerates adoption, with the US accounting for over 48% of global CGM device usage. More than 2.5 million US citizens currently use CGM systems, and the number is rising due to Medicare expansion that now covers CGM for over 6 million eligible senior patients.

The penetration of sensor-augmented insulin pumps is growing, with over 1.4 million US pump users, creating significant demand for CGM-pump integration. Regulatory approvals from the FDA have accelerated product launches, with over 15 new CGM technologies approved between 2020–2024, including factory-calibrated sensors and 14–180-day implantable systems. Adoption is also being driven by the increasing prevalence of obesity, which affects over 41.9% of US adults, increasing diabetes risk and expanding the target population. Continuous Glucose Monitoring (CGM) Market Insights in the US indicate strong potential for long-wear sensors, hospital-grade remote patient monitoring, and employer-sponsored wellness programs.

Key Findings

Key Market Driver: Approximately 62% of global diabetes patients require frequent glucose monitoring, driving CGM adoption, while 58% demand minimally invasive solutions, and 54% prefer real-time digital tracking systems for better glycemic control.
Major Market Restraint: Around 47% of patients consider CGM devices costly, 38% experience limited insurance reimbursement, and 33% express concerns about sensor accuracy variations affecting long-term trust in CGM devices.
Emerging Trends: Nearly 66% prefer long-wear sensors, 52% demand smartphone integration, 49% adopt AI-based predictive alerts, and 45% of new users shift toward factory-calibrated sensors for convenience.
Regional Leadership: North America holds over 48% share, Europe holds 27%, Asia-Pacific accounts for 18%, and the Middle East & Africa contributes 7%, establishing strong global CGM market dominance patterns.
Competitive Landscape: Dexcom holds 32% share, Abbott holds 38%, Medtronic holds 12%, while other manufacturers collectively hold 18%, showing strong competition among major global CGM device companies.
Market Segmentation: Sensors account for 55% of adoption, transmitters and receivers for 28%, and insulin pump integrations for 17%, driven by 64% preference for continuous data tracking across hospital and homecare settings.
Recent Development: Over 22% of new product launches include long-wear sensors, 18% feature implantable technology, 25% include smartphone integration, and 20% target AI-driven predictive analytics enhancements.

Continuous Glucose Monitoring (CGM) Market Latest Trends

Recent CGM Market Trends highlight a global shift toward digital health integration, AI-driven glucose prediction, and extended sensor wear duration. More than 70% of CGM systems launched since 2023 feature factory calibration, eliminating routine fingersticks. Disposable 14-day sensors now account for over 58% of global sensor usage, while implantable 90–180-day systems account for over 12%. With rising adoption across over 45% of Type 2 diabetes patients using insulin, the applicability of CGM solutions is expanding beyond traditional insulin-dependent users. AI-enabled predictive alerts are used by over 40% of new CGM adopters, offering improved hypoglycemia detection rates by up to 28%.

Remote patient monitoring programs deployed in hospitals increased CGM use by over 35% within intensive care units. The integration of CGM systems with smartwatches and wearable devices increased by over 42% in 2024, driven by demand for continuous health data tracking. In emerging markets, CGM adoption rose by 22% due to telehealth expansion and greater diabetes awareness. Continuous Glucose Monitoring (CGM) Market Outlook signals strong future adoption driven by mobile health ecosystems, predictive analytics, and automated insulin delivery systems. This Continuous Glucose Monitoring (CGM) Industry Report highlights technology-driven transformation shaping the market.

Continuous Glucose Monitoring (CGM) Market Dynamics

DRIVER

Increasing global diabetes prevalence

The rise in global diabetes cases—reaching 537 million adults and projected to surpass 643 million by 2030—is one of the strongest drivers of CGM adoption. With over 90% of diabetes cases being Type 2, healthcare systems are recommending continuous glucose tracking for better glycemic outcomes. Data shows that patients using CGM experience 30% fewer hypoglycemic events, improving long-term clinical outcomes. Approximately 52% of insulin-dependent patients prefer CGM over traditional fingerstick meters due to improved accuracy and convenience. The rising incidence of obesity, affecting over 650 million people globally, further increases diabetes risk. These clinical trends strongly support the Continuous Glucose Monitoring (CGM) Market Growth trajectory.

RESTRAINT

High cost of CGM devices

Although adoption is increasing, 47% of potential users report CGM devices as financially burdensome. In countries with limited insurance support, approximately 41% of patients delay adoption due to recurring sensor costs. Hospitals also report that over 29% of facilities face budget constraints when implementing CGM systems for in-patient monitoring. Additionally, 33% of patients express concern about sensor accuracy variations under certain conditions, which limits long-term loyalty. These financial and performance concerns act as major restraints within the Continuous Glucose Monitoring (CGM) Market Analysis.

OPPORTUNITY

Expansion of digital health ecosystem

The expanding digital health ecosystem offers major opportunities, with over 65% of new healthcare software integrating CGM data streams. The increasing use of telehealth—adopted by over 71% of hospitals in 2023—is facilitating remote diabetes management. Wearable device adoption, which exceeds over 1.1 billion global users, supports CGM-linked monitoring applications. Cloud-based diabetes management platforms have grown by over 35%, offering strong opportunities for device-software interoperability. As B2B healthcare providers prioritize connected care, Continuous Glucose Monitoring (CGM) Market Opportunities continue to grow across telemedicine, AI analytics, and remote monitoring.

CHALLENGE

Data accuracy and device interoperability

A major challenge includes variability in accuracy due to physiological factors, with 25% of users reporting performance issues related to hydration and motion. Device interoperability is limited, as over 40% of CGM systems cannot seamlessly connect with all insulin pumps or digital platforms. Cybersecurity concerns affect over 33% of healthcare providers integrating cloud-connected CGM platforms. Manufacturers must address regulatory hurdles, as over 18% of product approvals face delays due to performance validation requirements. These barriers impact adoption within the Continuous Glucose Monitoring (CGM) Industry Analysis.

Continuous Glucose Monitoring (CGM) Market Segmentation

Sensors account for the largest adoption at 55%, transmitters and receivers contribute 28%, while insulin pump integration holds 17%, with homecare usage representing over 62% of total CGM applications.

BY TYPE

Transmitters & Receivers: Transmitters and receivers represent 28% of the CGM market, supporting Bluetooth and NFC connectivity across over 72% of new devices. These components enable continuous data transfer to smartphones, pumps, and monitoring apps. With more than 1.8 million users depending on real-time alerts, transmitters play a key role in diabetic safety. Manufacturers have improved battery life by over 22%, enabling transmitters to last up to three months. As CGM-pump integrations rise—used by over 40% of Type 1 patients—transmitter technology continues to evolve to support automated insulin delivery systems. This segment is crucial in the Continuous Glucose Monitoring (CGM) Market Report for connectivity advancement.

Sensors: Sensors hold the largest market share at 55%, supported by high consumption rates due to replacement cycles ranging from 10 to 90 days. More than 3.8 million sensors are used globally per month, indicating strong recurring demand. Accuracy improvements of 25% since 2020 have boosted patient confidence. With over 70% of new sensors offering factory calibration, user reliance on fingersticks is significantly reduced. Long-wear sensors lasting up to 180 days—adopted by 12% of advanced monitoring patients—are creating new business opportunities. Sensor innovation remains the backbone of Continuous Glucose Monitoring (CGM) Market Trends.

Insulin Pumps: Insulin pumps integrated with CGM systems account for 17% of the market and are used by over 1.4 million patients globally. CGM-enabled pumps reduce hypoglycemia events by over 27% and support automated insulin delivery, used by 42% of advanced pump users. Hybrid closed-loop systems show 30% improvement in time-in-range metrics, increasing clinical adoption. As more than 90% of pump manufacturers focus on CGM partnerships, this segment continues to expand. The transmitter-sensor-pump ecosystem strengthens the Continuous Glucose Monitoring (CGM) Industry Report.

BY APPLICATION

Hospital: Hospitals represent 38% of CGM adoption in clinical settings, with over 32% of ICU units using continuous glucose monitoring for critical patients. CGM reduces nurse workload by 29% and enhances glycemic management accuracy by 24%. During surgical and emergency care, CGM use has increased by 26% due to better real-time monitoring. As chronic disease admissions grow—affecting over 18 million diabetic hospitalizations annually—CGM implementation becomes essential.

Homecare: Homecare accounts for 62% of CGM usage, driven by rising wearable adoption and patient self-management trends. More than 2.5 million individuals in home settings use CGM systems for daily monitoring. Mobile app connectivity is used by over 78% of homecare users, improving monitoring compliance by 22%. Long-wear sensors and smartphone-linked transmitters support decentralized diabetes management at scale. Homecare dominance defines Continuous Glucose Monitoring (CGM) Market Outlook.

Continuous Glucose Monitoring (CGM) Market Regional Outlook

North America leads with 48% share, Europe follows with 27%, Asia-Pacific contributes 18%, while the Middle East & Africa accounts for 7%, reflecting global CGM market expansion.

NORTH AMERICA

North America holds over 48% of the global CGM market due to high diabetes prevalence, with over 37 million patients and advanced technology adoption. The US accounts for 85% of regional CGM usage, supported by strong insurance penetration exceeding 90%. More than 65% of Type 1 patients in the region use CGM systems. Canada’s adoption rate grew by 22% in 2023, driven by expanded reimbursement. Strong manufacturer presence fuels Continuous Glucose Monitoring (CGM) Market Share in the region.

EUROPE

Europe holds 27% of the market, supported by widespread CGM adoption across Germany, France, the UK, and Italy. The region reports over 61 million diabetes patients, creating strong demand for monitoring devices. Germany alone contributes over 28% of Europe’s CGM usage. Government health programs cover over 72% of sensor costs in several Western European nations. Continuous Glucose Monitoring (CGM) Market Forecast for Europe indicates strong growth through digital health integration.

ASIA-PACIFIC

Asia-Pacific accounts for 18% of global CGM adoption, driven by high diabetes prevalence—exceeding 116 million patients in China and 77 million in India. Japan contributes over 14% of regional CGM use due to advanced healthcare infrastructure. Adoption increased by 22% in 2024, driven by telehealth expansion. Continuous Glucose Monitoring (CGM) Market Trends indicate strong demand for cost-effective sensors.

MIDDLE EAST & AFRICA

The Middle East & Africa region holds 7% share, supported by a diabetes prevalence exceeding 24% in Gulf countries. Saudi Arabia and the UAE represent over 48% of regional CGM adoption. Africa shows growing demand due to rising diabetes cases exceeding 28 million. Continuous Glucose Monitoring (CGM) Market Insights highlight emerging opportunities driven by urbanization and lifestyle changes.

List of Top Continuous Glucose Monitoring (CGM) Companies

Medtronic
i-SENS, Inc.
GlucoMenDay
Dexcom
Abbott
OSANG Healthcare Co., Ltd.
TaiDoc Technology Corporation
Sanwa Kagaku Kenkyusho Co., Ltd.
Senseonics

Top Two Companies with Highest Market Share

Abbott controls approximately 38% of the global CGM market share due to strong adoption of its wearable sensor systems across over 60 countries.
Dexcom holds around 32% market share, supported by high usage in the US and Europe, and strong adoption of smartphone-connected CGM solutions.

Investment Analysis and Opportunities

Investment activity in the Continuous Glucose Monitoring (CGM) market has accelerated due to rapid digital health adoption, rising diabetes cases, and growing demand for long-wear sensors. More than $4.2 billion equivalent in medical device investments were directed toward diabetes technologies in 2023, with CGM accounting for over 28% of device innovation pipelines by companies in the US, Europe, and Asia. Over 55% of new funding allocations target AI-based glucose prediction, while 32% focus on extended-life sensor materials. Strategic partnerships increased by over 40% between 2022–2024 as CGM manufacturers collaborate with cloud-health platforms and telemedicine providers.

Institutional investors are increasingly entering the market, with private equity investments in diabetes management technologies rising by 22% in 2023. Asia-Pacific markets show strong investment potential due to diabetes prevalence exceeding 11.9% in China and 9.6% in India. B2B procurement opportunities are rising in hospital groups, where CGM deployment increased by 35% in 2024 for in-patient monitoring. The Continuous Glucose Monitoring (CGM) Market Opportunities section identifies key areas for investors including implantable CGM systems, AI-enhanced platforms, pump-CGM integrations, insurer-driven value-based care programs, and next-generation wearable sensors.

New Product Development

New product development in the CGM market is accelerating with innovations targeting improved accuracy, extended wear time, and seamless digital connectivity. More than 15 new CGM products were launched globally between 2023–2025. Next-generation sensors now offer wear time of 90 to 180 days, representing a 22% increase in sensor longevity. AI-powered alerts improve hypoglycemia detection accuracy by up to 28%, reducing emergency incidents among high-risk patients. Smartphone integration is included in over 70% of new product launches, enhancing patient monitoring.

Manufacturers are reducing calibration requirements, with over 60% of devices launched post-2023 being factory calibrated. The development of fully implantable sensors—adopted by over 12% of advanced CGM users—marks a major innovation shift. Many companies focus on flexible biosensor materials, improving comfort and reducing insertion-related issues by 19%. Bluetooth 5.0 integration enhances data transfer speed by over 30%, supporting advanced pump-CGM communication. Cross-platform interoperability remains a major NPD priority, with over 40% of manufacturers working on universal data protocols. The Continuous Glucose Monitoring (CGM) Industry Report highlights strong NPD initiatives driven by sensor accuracy, real-time analytics, and hybrid closed-loop automation trends.

Five Recent Developments

Senseonics launched a 180-day implantable sensor in 2024, increasing wear duration by 50% compared to prior models.
Abbott introduced a 15-day disposable sensor, improving accuracy by 22% through upgraded biosensing materials.
Dexcom released smartphone-only data transmission technology, eliminating the need for receivers for over 2.3 million users.
Medtronic expanded pump-CGM automation, improving time-in-range metrics by 30% for hybrid closed-loop users.
i-SENS introduced cost-optimized sensors, reducing per-unit cost by 18%, promoting adoption in Asia-Pacific.

Report Coverage of Continuous Glucose Monitoring (CGM) Market

This Continuous Glucose Monitoring (CGM) Market Research Report provides comprehensive coverage of global adoption, technology advancements, regional shares, segmentation insights, and competitive analysis. It analyzes market performance across over 50 countries, highlighting diabetes prevalence exceeding 537 million global cases, and how this drives strong demand for CGM devices. Report coverage includes product breakdown across sensors, transmitters, receivers, and insulin pump integrations, which collectively support over 2.5 million homecare users globally. The study examines clinical use in hospitals, where CGM deployment exceeds 32% of ICUs, and homecare adoption accounting for 62% of total usage.

Regional insights cover North America’s 48% share, Europe’s 27%, Asia-Pacific’s 18%, and MEA’s 7%. Competitive coverage includes leading companies such as Abbott, Dexcom, Medtronic, and Senseonics, with detailed review of product innovations involving factory-calibrated sensors, implantable systems, and smartphone-linked monitoring. The report emphasizes Continuous Glucose Monitoring (CGM) Market Trends, Market Growth patterns, and CGM Market Outlook supported by AI-enhanced analytics and digital health integration. It provides B2B-focused insights for healthcare providers, manufacturers, distributors, and investors on emerging CGM Market Opportunities across disease management, telehealth, and automated insulin delivery.